Profile data is unavailable for this security.
About the company
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
- Revenue in USD (TTM)22.96m
- Net income in USD-163.30m
- Incorporated2005
- Employees117.00
- LocationAnaptysBio Inc10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 362-6295
- Fax+1 (858) 362-6296
- Websitehttps://www.anaptysbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 12.68m | -232.03m | 888.74m | 55.00 | -- | 3.10 | -- | 70.07 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 911.57m | 586.00 | -- | 0.8056 | -- | 25.47 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 927.56m | 171.00 | -- | 1.53 | -- | 45.35 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Humacyte Inc | 0.00 | -105.70m | 987.21m | 183.00 | -- | 37.75 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| CareDx Inc | 275.11m | -183.19m | 989.59m | 635.00 | -- | 3.84 | -- | 3.60 | -3.43 | -3.43 | 5.16 | 4.95 | 0.5611 | 5.35 | 4.61 | 433,245.70 | -37.36 | -17.54 | -43.69 | -20.85 | 62.94 | 65.50 | -66.59 | -27.78 | 4.03 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 995.85m | 82.00 | -- | 3.36 | -- | 453.69 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 996.27m | 96.00 | -- | 2.60 | -- | 3,459.27 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 999.96m | 24.00 | -- | 4.45 | -- | 99,995.91 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Pharvaris NV | 0.00 | -115.31m | 1.01bn | 82.00 | -- | 2.58 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 1.01bn | 117.00 | -- | 21.13 | -- | 43.97 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Silence Therapeutics plc | 34.08m | -45.09m | 1.01bn | 115.00 | -- | 6.63 | -- | 29.77 | -0.3962 | -0.3962 | 0.2893 | 1.15 | 0.1829 | -- | 5.37 | 296,333.80 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 1.04bn | 140.00 | -- | 3.94 | -- | 27.98 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.08bn | 267.00 | -- | -- | -- | 2.61 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| MiMedx Group Inc | 334.51m | 71.52m | 1.11bn | 895.00 | 20.04 | 7.15 | 13.99 | 3.33 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Data as of Jul 24 2024. Currency figures normalised to AnaptysBio Inc's reporting currency: US Dollar USD
62.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Mar 2024 | 7.52m | 27.53% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.49m | 5.44% |
| Tang Capital Management LLCas of 31 Mar 2024 | 1.33m | 4.87% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.31m | 4.80% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.21m | 4.42% |
| Great Point Partners LLCas of 31 Mar 2024 | 976.98k | 3.58% |
| First Light Asset Management LLCas of 31 Mar 2024 | 944.11k | 3.46% |
| Point72 Asset Management LPas of 31 Mar 2024 | 864.10k | 3.16% |
| Palo Alto Investors LPas of 31 Mar 2024 | 799.91k | 2.93% |
| Mangrove Partnersas of 31 Mar 2024 | 689.52k | 2.52% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
